Abbott Laboratories Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Abbott Laboratories on September 15, 2022. The report details corporate governance changes effective as of the filing date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and does not contain financial performance data.
Material Changes
- Board Expansion: The Board of Directors size was increased from twelve to thirteen persons.
- New Director Appointment: Claire Babineaux-Fontenot was named to the Board of Directors.
- Bylaw Amendment: Article III, Section 2 of the By-Laws was amended to reflect the new board size.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the effective date of Claire Babineaux-Fontenot's appointment to the Board.
- Confirm the updated total number of directors on the Board (13).
- Review the amended By-Laws (Exhibit 3.1) for any additional governance changes.